| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 55 | 44.1x | 17.8x | Around median | |
Growth | 61 | 11.9% | 7.1% | Around median | |
Quality | 66 | 2.9% | 4.5% | Around median | |
Safety | 71 | 1.2x | 2.6x | Top tier | |
Capital Return | 71 | — | 2.12% | Top tier | |
Momentum | 57 | 26.1% | 2.9% | Around median | |
Sentiment | 61 | 11 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Envista Holdings operates in the global dental market through a portfolio combining diagnostic equipment, consumables, orthodontics, dental implants, software, and related services. The company generates revenue through two main segments: Equipment & Consumables, which includes diagnostics and consumables, and Specialty Products & Technologies, which includes orthodontics and implant products; it also owns specific brands and platforms such as Spark, Damon Ultima, Implant Direct, and Alpha-Bio Tec. This mix gives the company exposure to procedures that are less sensitive to economic fluctuations, such as endodontic treatments, restorative care, and infection prevention, alongside more elective categories such as orthodontics and dental implants.
In the second quarter of fiscal 2026, Envista recorded revenue of $730.5 million, gross profit of $407.0 million, net income of $53.7 million, and earnings per share of $0.33, according to EDGAR data. This equates to a gross margin of approximately 55.7% and a net income margin of approximately 7.4%, compared with revenue of $705.5 million and net income of $38.7 million in the first quarter of fiscal 2026. Revenue for the twelve months ended in the second quarter of fiscal 2026 was approximately $2.8 billion, with net income of $67.7 million.
Operating growth in the second quarter of fiscal 2026 was broad-based across both segments: core sales in Equipment & Consumables grew 8.5%, driven by high-single-digit growth in consumables and diagnostics, while core sales in Specialty Products & Technologies grew 3.1%. Spark achieved double-digit growth, and implants grew at a low-single-digit rate, while brackets and wires sales declined at a high-single-digit rate. On an adjusted basis, EBITDA margin was 14.7%, up 230 basis points, with adjusted EBITDA growth of 28% and adjusted earnings per share growth of 58% year over year.
Automated analysis for informational purposes only — not investment advice.
The analysts' average price target is $29.14, within a wide range of $23 to $34, while the consensus rates the stock Neutral; the average is only $1.28 below the 52-week range high of $30.42. The 52-week range extends from $18.77 to $30.42, and no valid price-to-earnings ratio is available in the data, so NVST's valuation depends more heavily on achieving adjusted earnings per share guidance of between $1.50 and $1.55 for fiscal 2026 and sustaining margin expansion, weighed against China risks and slower second-half growth.
Figures in the text are as of 2026-08-31; the live price is shown at the top of the page.
Revenue reached $730.5 million, gross profit was $407.0 million, and net income was $53.7 million in the second quarter of fiscal 2026. Core sales grew 5%, with a $17 million contribution from volume and $12 million from net pricing. On an adjusted basis, EBITDA margin increased to 14.7%, and earnings per share grew 58% year over year.
On August 5, 2026, management raised its core growth guidance to a range of between 3.5% and 4.5%. It expects adjusted EBITDA growth of between 11% and 14% and adjusted earnings per share of between $1.50 and $1.55. It also expects free cash flow conversion of approximately 100% of adjusted net income and an annual tax rate of approximately 26%.
The company launched ZenSeal Pro in the second quarter of fiscal 2026, an endodontic sealer designed to reduce material waste by approximately one-third within a category valued at more than $1 billion. It also launched DemiPro and expanded Ormco Digital Bonding to include all bracket systems. In implants, the S series and Versah technology performed ahead of their launch and acquisition plans, and approximately one-quarter of S series sales came from competitive conversions.
Envista expects the first round of VBP for orthodontics and the second round for dental implants to be implemented in the second half of fiscal 2026. Management expects significant pressure on orthodontic pricing, while estimating implant price declines of between 10% and 15%. The company is relying on its market position, channel inventory replenishment, and share gains to offset pricing, but it did not specify a confirmed net impact from the second round for implants.
The business generated free cash flow of $105 million in the second quarter of fiscal 2026, up $29 million year over year, with cash conversion of 158%. Capital expenditures were $14 million, and cash flow included a refund related to IEEPA tariffs paid in 2025. The company also repurchased 2.4 million shares at an average of $24 per share, and net debt remained at 0.7 times adjusted EBITDA.
The analyst consensus rates NVST Neutral, with an average price target of $29.14. Targets range from $23 to $34, revealing meaningful differences in assessments of the impact of margin improvement and China risks. The average target is below the 52-week range high of $30.42, while the data does not provide a valid price-to-earnings ratio that can be relied upon.
